chr19-11039554-G-T
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PVS1_ModeratePM2
The NM_001387283.1(SMARCA4):c.4266+1G>T variant causes a splice donor, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000696 in 1,436,088 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001387283.1 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCA4 | NM_001387283.1 | c.4266+1G>T | splice_donor_variant, intron_variant | ENST00000646693.2 | NP_001374212.1 | |||
SMARCA4 | NM_003072.5 | c.4171-1753G>T | intron_variant | ENST00000344626.10 | NP_003063.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.4266+1G>T | splice_donor_variant, intron_variant | NM_001387283.1 | ENSP00000495368.1 | |||||
SMARCA4 | ENST00000344626.10 | c.4171-1753G>T | intron_variant | 1 | NM_003072.5 | ENSP00000343896.4 | ||||
SMARCA4 | ENST00000643549.1 | c.4167+1G>T | splice_donor_variant, intron_variant | ENSP00000493975.1 | ||||||
SMARCA4 | ENST00000541122.6 | c.4072-1744G>T | intron_variant | 5 | ENSP00000445036.2 | |||||
SMARCA4 | ENST00000643296.1 | c.4072-1744G>T | intron_variant | ENSP00000496635.1 | ||||||
SMARCA4 | ENST00000644737.1 | c.4072-1744G>T | intron_variant | ENSP00000495548.1 | ||||||
SMARCA4 | ENST00000589677.5 | c.4072-1744G>T | intron_variant | 5 | ENSP00000464778.1 | |||||
SMARCA4 | ENST00000643995.1 | c.3583-1744G>T | intron_variant | ENSP00000496004.1 | ||||||
SMARCA4 | ENST00000644963.1 | c.2815-1744G>T | intron_variant | ENSP00000495599.1 | ||||||
SMARCA4 | ENST00000644065.1 | c.2797-1744G>T | intron_variant | ENSP00000493615.1 | ||||||
SMARCA4 | ENST00000642350.1 | c.2656-1744G>T | intron_variant | ENSP00000495355.1 | ||||||
SMARCA4 | ENST00000643857.1 | c.2524-1744G>T | intron_variant | ENSP00000494159.1 | ||||||
SMARCA4 | ENST00000538456.4 | c.328-1744G>T | intron_variant | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.96e-7 AC: 1AN: 1436088Hom.: 0 Cov.: 26 AF XY: 0.00 AC XY: 0AN XY: 713946
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 11, 2023 | This sequence change affects a donor splice site in intron 30 of the SMARCA4 gene. Loss-of-function variants in SMARCA4 are known to be pathogenic (PMID: 24658001, 24658002). However, tissue-specific alternative splicing of SMARCA4 gene results in functional isoforms lacking in-frame exon 30 (also known as exon 28B, PMID: 18437052). For this reason the clinical significance of loss of function variants in exon 30 is currently uncertain. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. Disruption of this splice site has been observed in at least one individual who was not affected with SMARCA4-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 408654). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 03, 2024 | The c.4266+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 29 of the SMARCA4 gene. This nucleotide position is highly conserved in limited sequence alignment. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site. RNA studies have demonstrated that this alteration results in a transcript predicted to lead to a protein with an in-frame loss of the 32 amino acids of coding exon 29. However, the exact functional impact of the deleted amino acids is unknown as this region of the SMARCA4 gene is excluded from other biologically relevant transcripts (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at